Genascence to Present Full Data from Phase 1 Clinical Trial on GNSC-001, Company’s Lead Program in Osteoarthritis, at European Society of Gene & Cell Therapy 30th Annual Congress

Genascence Corporation, a clinical-stage biotechnology company revolutionizing the treatment of prevalent musculoskeletal diseases with gene therapy using technology discovered at the University of Florida, announced that data from the Phase 1 clinical trial of GNSC-001 for the treatment of osteoarthritis (OA) demonstrated that it was safe and well tolerated. 

“The Horse’s Mouth” with Enrico Levi of Inzecto

The Horse’s Mouth is a talk show where Tom McManus’s guests sidle up to his bar to discuss the intersection of sports, business, and life. Today, Tom sits with Enrico Levi of Inzecto, a UF startup licensing mosquito control technology created by Levi, Roberto Pereira, and principal investigator Philip Koehler at the UF College of Agriculture and Food Sciences.